GlassScriptPhysician profile
Nimrod Blank
NPI 1255709218
$6,301.70
in general payments reported to CMS, 2019-2025
30 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,084 · 2020: $1,733 · 2021: $691 · 2022: $242 · 2023: $237 · 2024: $1,153 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,623.75 | 2019-2021 | |
| Boston Scientific Corporation | $1,120.98 | 2019-2024 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $395.38 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $230.46 | 2019-2021 | |
| Astellas Pharma US INC | $178.99 | 2022 | |
| Tactile Systems Technology INC | $175.23 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Novo Nordisk INC | $148.34 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.74 | 2024 | |
| Medtronic, INC. | $122.79 | 2023-2025 | Venaseal, Closurefast |
| Recor Medical INC | $118.17 | 2024 | Paradise Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.28 | 2024 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $104.21 | 2024 | Arcalyst |
| Baxter Healthcare | $90.85 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $88.25 | 2024 | |
| Amgen INC. | $82.87 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $79.74 | 2024 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $77.53 | 2021 | |
| Kestra Medical Technology Services, INC. | $69.44 | 2024-2025 | Assure Wcd |
| Shockwave Medical, INC | $52.11 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $51.94 | 2024-2025 | Verquvo |
| Cardiovascular Systems INC. | $42.42 | 2020-2021 | |
| Angiodynamics, INC. | $34.86 | 2022 | |
| Cvrx, INC. | $30.38 | 2023 | Barostim Neo System |
| Livanova USA, INC. | $24.31 | 2019 | |
| Akcea Therapeutics, INC. | $22.64 | 2020 | |
| Corcept Therapeutics | $22.40 | 2021 | |
| Edwards Lifesciences Corporation | $20.70 | 2019 | |
| Pfizer INC. | $19.11 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.28 | 2021 | |
| Amarin Pharma, INC. | $16.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimrod Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.